CA2306692A1 - Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers - Google Patents
Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers Download PDFInfo
- Publication number
- CA2306692A1 CA2306692A1 CA002306692A CA2306692A CA2306692A1 CA 2306692 A1 CA2306692 A1 CA 2306692A1 CA 002306692 A CA002306692 A CA 002306692A CA 2306692 A CA2306692 A CA 2306692A CA 2306692 A1 CA2306692 A1 CA 2306692A1
- Authority
- CA
- Canada
- Prior art keywords
- ch2f
- asp
- compound
- cell death
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/16—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Abstract
La présente invention concerne de nouveaux dipeptides représentés par la formule générale (I), dans laquelle R1-R3 et AA sont définis. Les composés correspondant à la formule (I) sont de puissants inhibiteurs de la mort cellulaire programmée. Par conséquent, les inhibiteurs décrits dans la présente invention peuvent retarder ou bloquer la mort cellulaire dans diverses conditions cliniques pouvant donner lieu à la perte de cellules, de tissus ou de la totalité des organes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6167697P | 1997-10-10 | 1997-10-10 | |
| US60/061,676 | 1997-10-10 | ||
| PCT/US1998/021232 WO1999018781A1 (fr) | 1997-10-10 | 1998-10-09 | Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2306692A1 true CA2306692A1 (fr) | 1999-04-22 |
| CA2306692C CA2306692C (fr) | 2010-09-21 |
Family
ID=22037372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2306692A Expired - Fee Related CA2306692C (fr) | 1997-10-10 | 1998-10-09 | Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1033910A4 (fr) |
| JP (1) | JP4439111B2 (fr) |
| KR (1) | KR100580333B1 (fr) |
| CN (1) | CN1138472C (fr) |
| AU (1) | AU741203B2 (fr) |
| BR (1) | BR9814817A (fr) |
| CA (1) | CA2306692C (fr) |
| EA (1) | EA200000409A1 (fr) |
| NO (1) | NO20001323L (fr) |
| WO (1) | WO1999018781A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| KR20010041905A (ko) * | 1998-03-16 | 2001-05-25 | 시토비아 인크. | 디펩티드 카스파제 억제제 및 이의 용도 |
| DE69932434D1 (de) | 1998-05-29 | 2006-08-31 | Mochida Pharm Co Ltd | Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE348163T1 (de) | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| EP1180991B1 (fr) | 1999-02-01 | 2010-05-19 | Cytovia, Inc. | Acide de gomme-gute derives en tant qu'activateurs de caspases et inducteurs d'apoptose |
| EP1165490B1 (fr) | 1999-03-16 | 2006-08-16 | Cytovia, Inc. | Inhibiteurs de caspases 2-aminobenzamidiques substitues et leur utilisation |
| CA2369619A1 (fr) * | 1999-04-09 | 2000-10-19 | Cytovia, Inc. | Inhibiteurs de la caspase et leur utilisation |
| US6495522B1 (en) | 1999-08-27 | 2002-12-17 | Cytovia, Inc. | Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
| US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| US6303374B1 (en) | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
| DE10006889A1 (de) * | 2000-02-16 | 2001-09-06 | Procorde Gmbh | Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen |
| US6689784B2 (en) * | 2000-03-29 | 2004-02-10 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
| SI1268425T1 (sl) | 2000-03-29 | 2008-04-30 | Vertex Pharma | Zaviralci karbamat kaspaze in uporaba le-teh |
| NZ516918A (en) | 2000-05-23 | 2004-06-25 | Vertex Pharma | Caspase inhibitors and uses thereof |
| US20020052323A1 (en) * | 2000-08-30 | 2002-05-02 | Jinhai Wang | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents |
| JP2004509120A (ja) * | 2000-09-13 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼ阻害剤およびそれらの用途 |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| MXPA03009647A (es) | 2001-04-19 | 2004-01-29 | Vertex Pharma | Heterociclildicarbamidas como inhibidores de caspasa. |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| MXPA05001367A (es) | 2002-08-02 | 2005-04-28 | Vertex Pharma | Composiciones de pirazol utiles como inhibidores de gsk-3. |
| US20060212020A1 (en) * | 2002-10-10 | 2006-09-21 | Lynne Rainen | Sample collection system with caspase inhibitor |
| CA2580796C (fr) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Molecules fc modifiees ayant des peptides inserees dans les regions de boucle interne |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| WO2008137619A2 (fr) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles et pyrazoles qui s'utilisent comme inhibiteurs de kinase |
| WO2009018415A1 (fr) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Procédé de préparation de la 5-fluoro-1h-pyrazolo[3,4-b]pyridin-3-amine et des dérivés de celle-ci |
| FR2923160B1 (fr) * | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
| AU2009288200A1 (en) | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| CN106317161B (zh) * | 2015-06-29 | 2020-05-15 | 深圳翰宇药业股份有限公司 | 一种氟甲基酮肽系列化合物的制备方法 |
| CN117045634B (zh) * | 2022-05-06 | 2025-10-10 | 北京康蒂尼药业股份有限公司 | 一种二肽衍生物组合物及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015577A1 (fr) * | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
| DE69226820T2 (de) * | 1991-06-21 | 1999-05-12 | Merck & Co., Inc., Rahway, N.J. | Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen |
| RU2206611C2 (ru) * | 1991-08-30 | 2003-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ |
| US5462939A (en) * | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
| JPH0789951A (ja) * | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
| US5565430A (en) * | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
| ATE310528T1 (de) * | 1996-09-12 | 2005-12-15 | Idun Pharmaceuticals Inc | Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie |
-
1998
- 1998-10-09 AU AU97930/98A patent/AU741203B2/en not_active Ceased
- 1998-10-09 BR BR9814817-6A patent/BR9814817A/pt not_active IP Right Cessation
- 1998-10-09 KR KR1020007003882A patent/KR100580333B1/ko not_active Expired - Fee Related
- 1998-10-09 EA EA200000409A patent/EA200000409A1/ru unknown
- 1998-10-09 WO PCT/US1998/021232 patent/WO1999018781A1/fr not_active Ceased
- 1998-10-09 JP JP2000515426A patent/JP4439111B2/ja not_active Expired - Fee Related
- 1998-10-09 CN CNB988100223A patent/CN1138472C/zh not_active Expired - Fee Related
- 1998-10-09 CA CA2306692A patent/CA2306692C/fr not_active Expired - Fee Related
- 1998-10-09 EP EP98952166A patent/EP1033910A4/fr not_active Withdrawn
-
2000
- 2000-03-14 NO NO20001323A patent/NO20001323L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9814817A (pt) | 2002-01-08 |
| EA200000409A1 (ru) | 2000-10-30 |
| NO20001323D0 (no) | 2000-03-14 |
| EP1033910A1 (fr) | 2000-09-13 |
| AU9793098A (en) | 1999-05-03 |
| NO20001323L (no) | 2000-06-13 |
| CA2306692C (fr) | 2010-09-21 |
| CN1301131A (zh) | 2001-06-27 |
| AU741203B2 (en) | 2001-11-22 |
| KR100580333B1 (ko) | 2006-05-16 |
| CN1138472C (zh) | 2004-02-18 |
| WO1999018781A1 (fr) | 1999-04-22 |
| JP2001519358A (ja) | 2001-10-23 |
| EP1033910A4 (fr) | 2004-11-24 |
| JP4439111B2 (ja) | 2010-03-24 |
| KR20010031053A (ko) | 2001-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6727227B1 (en) | Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application | |
| US6153591A (en) | Dipeptide caspase inhibitors and the use thereof | |
| JP5647995B2 (ja) | 新規な抗老化ペプチド、並びにそれを含む化粧品及び/または製薬組成物 | |
| WO2021033830A1 (fr) | Peptide ayant une activité favorisant la pousse des cheveux et son utilisation | |
| JPS61212598A (ja) | インシユリン化合物 | |
| KR20140026329A (ko) | 사이클로스포린 유사체 | |
| CA2123516A1 (fr) | Sels organiques de la n,n'-diacetylcystine | |
| CN102272150B (zh) | 新的抗衰老肽及含有所述肽的化妆品和/或药物组合物 | |
| KR20010031053A (ko) | 디펩티드 고사 억제제 및 그의 용도 | |
| CN108699112A (zh) | 呈现生发和/或育发促进活性的肽及其的用途 | |
| CZ287816B6 (en) | Peptide, process of its preparation, pharmaceutical preparation in which it is comprised and use thereof | |
| BR112014003051B1 (pt) | Polipeptídeo, composição para estimular o crescimento de cabelo e uso dos mesmos | |
| KR101713127B1 (ko) | 저색소증 개선 및 지방 형성 억제 효능을 갖는 펩타이드 및 이의 용도 | |
| WO1990008130A1 (fr) | Derives d'acide gras polyinsatures, compositions pharmaceutiques contenant ces derives, procede pour leur preparation et utilisation de ces derives comme medicament | |
| WO2006059227A1 (fr) | C-glycopeptides gem-difluores, leur preparation et leur utilisation pour la conservation de matieres biologiques et/ou la cryochirurgie | |
| US20070099845A1 (en) | Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof | |
| US6831162B2 (en) | Protein/polypeptide-k obtained from Momordica charantia and a process for the extraction thereof | |
| DE69431603T2 (de) | Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins | |
| FR2900656A1 (fr) | Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation notamment pour la preservation de materiaux biologiques | |
| US5663148A (en) | Anaphylatoxin receptor ligands containing lipophilic residues | |
| US20060160748A1 (en) | Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof | |
| EP0998494B1 (fr) | Neuropeptides obtenus a partir de guepes pompiles | |
| US9365633B2 (en) | Peptide preparations and peptides with antitumour activity | |
| RU94018525A (ru) | Замещенные 2-гидрокси-3[1-(1н-имидазол-4-ил)алкил]-бензолкарбоксимидамиды, способы их получения и фармацевтическая композиция на их основе | |
| JP3972104B2 (ja) | 新規なヘクサペプチド及びアンジオテンシン変換酵素阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141009 |